Inclusion Criteria

- INCLUSION CRITERIA:

1. Measurable metastatic ocular melanoma.

2. Confirmation of diagnosis of metastatic ocular melanoma by the Laboratory of
Pathology of the NCI.

3. 3 or fewer brain metastases. Note: If lesions are symptomatic or greater than or
equal to 1 cm each, these lesions must have been treated and stable for 3 months
for the patient to be eligible.

4. Greater than or equal to 18 years of age and less than or equal to age 70.

5. Able to understand and sign the Informed Consent Document

6. Clinical performance status of ECOG 0 or 1

7. Life expectancy of greater than three months

8. Patients of both genders must be willing to practice birth control from the time
of enrollment on this study and for up to four months after receiving the
preparative regimen.

9. Serology:

- Seronegative for HIV antibody. (The experimental treatment being evaluated
in this protocol depends on an intact immune system. Patients who are HIV
seropositive can have decreased immune-competence and thus be less
responsive to the experimental treatment and more susceptible to its
toxicities.)

- Seronegative for hepatitis B antigen, and seronegative for hepatitis C
antibody. If hepatitis C antibody test is positive, then patient must be
tested for the presence of antigen by RT-PCR and be HCV RNA negative.

- Women of child-bearing potential must have a negative pregnancy test
because of the potentially dangerous effects of the preparative
chemotherapy on the fetus.

10. Hematology

- Absolute neutrophil count greater than 1000/mm3 without the support of
filgrastim

- WBC greater than or equal to 3000/mm(3)

- Platelet count greater than or equal 100,000/ mm(3)

- Hemoglobin > 8.0 g/dl

11. Chemistry:

- Serum ALT/AST less than or equal to 3.5 times the upper limit of normal

- Serum creatinine less than or equal to 1.6 mg/dl

- Total bilirubin less than or equal to 2.0 mg/dl, except in patients with
Gilbert's Syndrome who must have a total bilirubin less than 3.0 mg/dl.

12. More than four weeks must have elapsed since any prior systemic therapy at the
time the patient receives the preparative regimen, and patients' toxicities must
have recovered to a grade 1 or less (except for toxicities such as alopecia or
vitiligo).

Note: Patients may have undergone minor surgical procedures within the past 3 weeks, as
long as all toxicities have recovered to grade 1 or less or as specified in the
eligibility criteria.

EXCLUSION CRITERIA:

1. Women of child-bearing potential who are pregnant or breastfeeding because of the
potentially dangerous effects of the preparative chemotherapy on the fetus or infant.

2. Active systemic infections, coagulation disorders or other active major medical
illnesses of the cardiovascular, respiratory or immune system, as evidenced by a
positive stress thallium or comparable test, myocardial infarction, cardiac
arrhythmias, obstructive or

restrictive pulmonary disease.

3. Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency
Disease).

4. Concurrent opportunistic infections (The experimental treatment being evaluated in
this protocol depends on an intact immune system. Patients who have decreased immune
competence may be less responsive to the experimental treatment and more susceptible
to its toxicities).

5. Concurrent systemic steroid therapy.

6. History of severe immediate hypersensitivity reaction to any of the agents used in
this study.

7. The following patients will be excluded from the high-dose aldesleukin arm (but may
be eligible for cells alone arm):

1. History of coronary revascularization or ischemic symptoms

2. Documented LVEF of less than or equal to 45%. Testing is required in patients
with:

- Clinically significant atrial and/or ventricular arrhythmias including but
not limited to: atrial fibrillation, ventricular tachycardia, second or
third degree heart block

- Age greater than or equal to 60 years old

3. Documented FEV1 less than or equal to 60% predicted tested in patients with:

- A prolonged history of cigarette smoking (20 pk/yrs of smoking)

- Symptoms of respiratory dysfunction

4. Clinically significant patient history which in the judgment of the Principal
Investigator would compromise the patient's ability to tolerate aldesleukin